Do I need progesterone with estrogen?
Progesterone can have an essential role in a menopause treatment plan: protecting the uterine lining while systemic estrogen treats symptoms. Whether you need it depends on whether you have a uterus, which estrogen you use and the dose and route of the proposed progestogen.
Why the uterus changes the answer
Systemic estrogen can stimulate the uterine lining. An appropriately prescribed progestogen counters that effect and reduces the risk of endometrial overgrowth. This is why a plan that helps hot flashes may contain two hormones even when estrogen is the medicine addressing that symptom.
The PEPI trial tested specific oral estrogen and progestogen regimens in postmenopausal women over three years. Its combined regimens, including cyclic oral micronized progesterone, protected against the excess endometrial hyperplasia seen with estrogen alone. That evidence establishes a role for the studied regimens; it does not make every progesterone product or schedule interchangeable.
When progesterone may not be needed for this purpose
After a total hysterectomy, uterine-lining protection is generally no longer the reason to prescribe a progestogen. There can be individual exceptions, including a history or surgery that requires a more specific plan. Tell the prescriber exactly which procedure you had; an endometrial ablation is different from removal of the uterus.
Low-dose local vaginal estrogen is another distinct situation. Guidance generally does not recommend adding a progestogen solely for that treatment. A systemic estrogen regimen and a low-dose local vaginal regimen should therefore be reviewed separately. Do not stop an existing progesterone prescription until the clinician has confirmed which situation applies to you.
Read: British Menopause Society: Progestogens and endometrial protection; Endocrine Society: Treatment of menopause symptoms.
A cream is not the same as a capsule
Oral progesterone evidence cannot be transferred to progesterone rubbed onto the skin. In a small study of 27 postmenopausal women receiving transdermal estrogen, sequential progesterone cream did not produce the expected protective change in the uterine lining. The British Menopause Society also advises that transdermal micronized progesterone is unlikely to provide sufficient protection.
This matters if you are considering a combined estrogen/progesterone cream. The presence of progesterone on its ingredient list does not establish adequate uterine protection. The prescriber needs to explain the protection strategy for that specific regimen, including whether a separate, supported progestogen approach is needed.
Read: Wren et al. Transdermal progesterone cream and the endometrium; British Menopause Society: Progestogens and endometrial protection.
What to discuss about oral progesterone
Approved oral progesterone labeling includes a specified regimen for prevention of endometrial hyperplasia in postmenopausal women with a uterus taking estrogen. It also describes dizziness and drowsiness. Discuss driving, daytime responsibilities, previous mood or tolerability concerns, and the ingredients in the actual dispensed product.
AnthologyRX’s current listed oral micronized progesterone capsules are an FDA-approved generic medication. The prescriber remains responsible for explaining why the medication is appropriate and how its dose fits your estrogen treatment. Your prescription label identifies the product dispensed.
Read: Prometrium prescribing information; FDA: Compounding questions and answers; Current micronized progesterone capsules: Bionpharma product label.
Keep the two prescriptions connected
Bring the name, strength and schedule of every estrogen and progesterone preparation you use, including products from another clinician. If estrogen changes, ask whether the protection plan needs review too. A change in route or dose deserves more than carrying over an old instruction by habit.
Know whom to contact about new, persistent or unexpected vaginal bleeding. Ask what follow-up applies to your health history and which symptoms warrant earlier assessment. A clear plan should explain the purpose of each medicine, how to take it and what would lead the clinician to adjust treatment. That clarity makes ongoing hormone care easier to manage.
Read: British Menopause Society: Progestogens and endometrial protection; Prometrium prescribing information.
Sources
- PEPI trial: Hormone therapy and the uterine lining
JAMA, 1996. Three-year randomized trial of specific oral estrogen and progestogen regimens in postmenopausal women.
- British Menopause Society: Progestogens and endometrial protection
Clinical guidance on dose, route and adequate estrogen opposition; UK licensing details are not US approval claims.
- Endocrine Society: Treatment of menopause symptoms
Guidance distinguishes systemic estrogen from low-dose vaginal estrogen when considering a progestogen.
- Wren et al. Transdermal progesterone cream and the endometrium
Climacteric, 2000. 27 postmenopausal women using transdermal estrogen plus sequential progesterone cream.
- Prometrium prescribing information
DailyMed, updated July 2026. Oral progesterone and the studied endometrial-protection regimen.
- FDA: Compounding questions and answers
Approved medicines and compounded finished preparations are distinct.
- Current micronized progesterone capsules: Bionpharma product label
Exact current catalog package identifiers match the approved generic capsules under ANDA200900. These listed capsules contain peanut oil and must not be used by people with peanut allergy.
